Retatrutide (Investigational)

Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist that represents the leading edge of pharmacological obesity treatment. By simultaneously activating three distinct metabolic receptors — GLP-1 for satiety and insulin secretion, GIP for glucose regulation and fat storage, and glucagon for energy expenditure — retatrutide creates a broader and more powerful metabolic reset than any previously approved agent. Eli Lilly's TRIUMPH-4 Phase 3 trial, results released in December 2025, produced the most dramatic weight loss data ever recorded for a pharmacological intervention: a mean 28.7 percent body weight reduction, approaching outcomes historically associated with bariatric surgery. This number is extraordinary in context — tirzepatide's dual-agonism produced 20.9 percent, meaning the addition of glucagon receptor activation contributed an estimated 8 percentage points of additional weight loss. Lilly has announced NDA filing plans for Q4 2026, meaning US regulatory approval could come in late 2027 if the review proceeds on a standard timeline. The drug is not yet available by prescription anywhere in the world as of May 2026. While efficacy dominates the narrative, real-world tolerability at these efficacy levels must be carefully characterized — greater fat mobilization and more aggressive appetite suppression may amplify GI side effects, and longer-term effects on bone density, lean muscle mass, and rebound weight gain after discontinuation require study. No cardiovascular outcomes trial data is yet available for retatrutide. Despite these limitations, retatrutide belongs in any 2026 GLP-1 ranking because its Phase 3 data are finalized, its regulatory timeline is concrete, and patients and clinicians should understand what is coming within 12 to 18 months.